Davion Healthcare Plc has announced an evolution of its commercial model to support the international rollout of its product portfolio and future acquisition strategy. The Board has decided to transition to a direct commercialisation model, enabling the company and its subsidiaries to transact directly with regional distribution partners and customers in target markets. This shift follows a review of its commercial strategy and is intended to provide greater control over product strategy, commercial execution, and customer relationships.

As part of this transition, Davion has exercised its contractual rights to terminate its existing global licensing and distribution arrangements relating to Davion BreastCheck. The company believes that direct commercialisation will establish a scalable commercial platform capable of supporting its existing product portfolio and future acquisitions.

To support this strategy, Davion has entered into an agreement to acquire a controlling interest in Solar Medical and Chemical Limited, a United Kingdom-based medical products distribution business. Upon completion, Solar Medical is intended to become Davion's principal commercial and distribution platform in the United Kingdom. This acquisition is expected to provide Davion with an owned UK operating capability and a scalable commercial infrastructure.

The UK platform will support the rollout and market development of several products, including Davion BreastCheck, Davion FootFlow, and Davion ThermaDerm. Outside the United Kingdom, Davion intends to appoint carefully selected regional distribution partners that will transact directly with the company and its subsidiaries.

Strategic Advantages

The revised commercial structure offers several strategic benefits:

• Direct oversight of product deployment and commercial execution
• An owned UK commercial and distribution capability
• Greater control over customer relationships and market development
• A scalable platform capable of supporting multiple products and future acquisitions
• A flexible framework for international expansion through regional partnerships

Jack Kaye, CEO of Davion Healthcare Plc, commented that this transition marks an important step in the company's evolution. He stated that the objective is to move beyond individual licensing arrangements and establish a scalable commercial platform capable of supporting multiple products across the portfolio. Kaye added that the addition of Solar Medical is intended to provide an owned operating capability in the United Kingdom and a platform for future growth.

The company expects to provide further updates regarding the completion of the Solar Medical transaction, product deployment plans, and regional partnership arrangements in due course. Davion continues to progress its proposed direct listing on the Nasdaq Global Market and remains engaged with the ongoing SEC review process.